Hypoxia inducible factor (HIF): its central role in renal cell cancer targeted therapy.
Brigham and Women's Hospital, Boston, MA, USA.
Kevin R
KR
Loughlin
D000970:Antineoplastic Agents / Q000627:therapeutic use; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008954:Models, Biological; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D000099162:Endothelial PAS Domain-Containing Protein 1
D000970:Antineoplastic Agents; D051792:Basic Helix-Loop-Helix Proteins; D051793:Hypoxia-Inducible Factor 1; D047428:Protein Kinase Inhibitors; D000099162:Endothelial PAS Domain-Containing Protein 1